Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab plus Herceptin in HER2-positive metastatic breast cancer after progression on Herceptin-based therapy
2005-003493-19Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pertuzumab and trastuzumab in breast cancer, sponsored by Roche. Primary endpoints: Objective Response and Clinical Benefit Response Rate. Started Dec 2005; status: completed.
02
Drugs
pertuzumabtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-003493-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003493-19.